Third-Party Tested ≥98% HPLC Purity — USA Shipped

Melanogenesis Research Guide

Melanotan-1: Mechanism, Handling & Research Guide

Also known as: Melanotan-1, Melanotan 1, Melanotan I, MT-1, MT-I, Afamelanotide, Scenesse, CUV1647, [Nle4-D-Phe7]-alpha-MSH, NDP-alpha-MSH, afamelanotide acetate

Key Facts

Melanotan-1 is a melanogenesis research peptide (C78H111N21O19, MW 1646.87 g/mol). Alpha-MSH analogue for melanogenesis and pigmentation research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification Linear synthetic tridecapeptide alpha-melanocyte-stimulating hormone (alpha-MSH) analogue; melanocortin-1 receptor (MC1R) agonist
Molecular Formula C78H111N21O19
Molecular Weight 1646.87 g/mol
Research Half-Life Short systemic half-life on the order of ~30 minutes to a few hours for the peptide reported in literature; afamelanotide is typically delivered as a slow-release implant in clinical studies
Form Lyophilized powder
Research Category Melanogenesis

What is Melanotan-1?

Melanotan 1, also designated Afamelanotide, is a linear synthetic tridecapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) with the substitution of Nle at position 4 and D-Phe at position 7, conferring modulated receptor binding affinity and metabolic stability. Melanotan 1 selectively activates melanocortin-1 receptor (MC1R), the primary receptor responsible for melanogenesis in epidermal melanocytes. MC1R activation triggers adenylyl cyclase-mediated cAMP elevation, which upregulates microphthalmia-associated transcription factor (MITF) and downstream eumelanin synthesis enzymes. Research published in the British Journal of Dermatology by Barnetson et al. (2006) demonstrated that Afamelanotide produced significant increases in melanin density without UV exposure in fair-skinned individuals, conferring a measurable photoprotective effect. Harms et al. in Photochemistry and Photobiology showed that Melanotan 1-induced eumelanin production provided DNA damage protection equivalent to moderate constitutive pigmentation. Studies in erythropoietic protoporphyria (EPP) patients published in the New England Journal of Medicine (Langendonk et al., 2015) demonstrated that Afamelanotide significantly increased pain-free time in sunlight. Compared to Melanotan 2, which is a cyclic heptapeptide acting non-selectively across MC1R through MC5R, Melanotan 1 is more selective for MC1R and therefore produces fewer off-target effects. Melanotan 2 additionally activates MC4R (associated with appetite and arousal), while Melanotan 1's selectivity makes it more suitable for focused pigmentation research. Store lyophilized Melanotan 1 at -20°C, protected from light. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. This peptide is studied by dermatologists, photobiologists, and researchers investigating melanocortin receptor pharmacology and photoprotective strategies.

Melanotan-1 Research Applications

In published and preclinical research, Melanotan-1 has been studied across the following areas:

  • Melanocortin receptor activation studies
  • Eumelanin production research
  • Anti-inflammatory and anti-fibrogenic studies
  • UV radiation protection research

Melanotan-1 in Research: Study Context

Published literature characterizes Melanotan-1 / afamelanotide ([Nle4-D-Phe7]-alpha-MSH) as a linear alpha-MSH analogue with high selectivity for the melanocortin-1 receptor (MC1R), driving cAMP-mediated eumelanin synthesis; controlled studies report increased epidermal melanin density and reduced UV-induced DNA damage (Barnetson et al.), and the implant form has been studied in erythropoietic protoporphyria for sunlight tolerance (Langendonk et al., NEJM). For laboratory research the lyophilized peptide is reconstituted with bacteriostatic water to a defined concentration such as 5.0 mg/mL (a 10 mg vial in 2 mL), stored at 2-8C, and protected from light. This product is for in-vitro and laboratory research use only, is not FDA-approved in this form, and carries no human concentration; investigators should reference the primary literature and document each lot's Certificate of Analysis (COA).

How Melanotan-1 Compares

Researchers frequently evaluate Melanotan-1 alongside related compounds:

  • Melanotan-1 vs Melanotan-2 — Cyclic, non-selective MC1R-MC5R agonist; contrasts with Melanotan-1's linear MC1R-selective pigmentation profile
  • Melanotan-1 vs PT-141 — MC3R/MC4R-directed melanocortin analogue derived from the melanotan line, studied for central arousal pathways rather than pigmentation

Melanotan-1 — Frequently Asked Questions

What is the molecular target of Melanotan-1 in the literature?
Melanotan-1 (afamelanotide) is characterized as a linear alpha-MSH analogue that selectively activates the melanocortin-1 receptor (MC1R) on melanocytes. MC1R activation raises intracellular cAMP, upregulating MITF and eumelanin-synthesis enzymes - the basis for the increased melanin density observed in controlled human studies.
How does Melanotan-1 differ from Melanotan-2 in published work?
Melanotan-1 is a linear tridecapeptide with high MC1R selectivity, while Melanotan-2 is a cyclic heptapeptide that activates MC1R through MC5R non-selectively, including the MC3R/MC4R pathways tied to arousal and appetite. The literature treats Melanotan-1 as the more receptor-selective pigmentation tool compound.
Is Melanotan-1 the same as an approved drug?
Afamelanotide (the implant brand Scenesse) has regulatory approvals for a narrow indication, but research-grade Melanotan-1 lyophilized peptide is not an FDA-approved product and is supplied strictly for in-vitro and laboratory research use only, with no human concentration. Each research lot should ship with a Certificate of Analysis documenting identity and purity.
Is Melanotan-1 legal to buy for research?
Melanotan-1 is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does Melanotan-1 come with a Certificate of Analysis?
Yes. Every batch of Melanotan-1 from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is Melanotan 1 and how does it work?
Melanotan 1 (afamelanotide) is a synthetic 13-amino acid linear analogue of alpha-melanocyte stimulating hormone (alpha-MSH). It selectively activates the MC-1R (melanocortin-1 receptor) on melanocytes, stimulating eumelanin production — the dark photoprotective pigment. Unlike Melanotan 2, which is cyclic and non-selective, Melanotan 1's linear structure provides more targeted MC-1R activation with minimal activity at other melanocortin receptor subtypes.
What research has been done on Melanotan 1?
Melanotan 1 (as afamelanotide/Scenesse) received FDA and EMA approval for erythropoietic protoporphyria (EPP). Published research in the New England Journal of Medicine demonstrated increased pain-free time in sunlight for EPP patients. Additional studies have explored its photoprotective potential in polymorphous light eruption, solar urticaria, and actinic keratosis prevention. Research in Pigment Cell & Melanoma Research showed MC-1R activation modulates DNA repair in UV-exposed melanocytes.
How does Melanotan 1 compare to Melanotan 2?
Melanotan 1 is a linear peptide with high MC-1R selectivity, producing pigmentation with fewer off-target effects. Melanotan 2 is a cyclic heptapeptide that non-selectively activates MC-1R through MC-5R, causing pigmentation plus sexual arousal (MC-3R/4R), melanocortin appetite-pathway signaling, and other melanocortin effects. Melanotan 1 has regulatory approval and more clinical safety data. Melanotan 2 is primarily a research tool for studying broad melanocortin pathway effects.

Research References

  1. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006.
  2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015.